Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy.

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 387, Issue 10037, Pages (June 2016)

Enhanced performance feedback and patient participation to improve hand hygiene compliance of health-care workers in the setting of established multimodal.

Volume 379, Issue 9824, Pages (April 2012)

Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase.

Volume 357, Issue 9273, Pages (June 2001)

Volume 367, Issue 9517, Pages (April 2006)

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS Reflate TB): a multicentre, phase 2, non-comparative, open-label,

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9322, Pages (June 2002)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 385, Issue 9984, Pages (June 2015)

Volume 11, Issue 4, Pages (April 2012)

Volume 376, Issue 9734, Pages (July 2010)

Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial Prof Mark C Steinhoff, MD, Prof Joanne Katz,

Long-term effects of hormone replacement therapy

Volume 389, Issue 10069, Pages (February 2017)

Controlling Ebola: key role of Ebola treatment centres

Infections related to totally implantable venous-access ports

Volume 376, Issue 9734, Pages (July 2010)

John N Nkengasong, Philip Onyebujoh The Lancet

Volume 385, Issue 9977, Pages (April 2015)

Volume 13, Issue 3, Pages (March 2012)

Long-term effects of hormone replacement therapy

Volume 366, Issue 9486, Pages (August 2005)

Ebola virus epidemic in war-torn eastern DR Congo

Ebola superspreading The Lancet Infectious Diseases

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

Volume 1, Issue 3, Pages (August 2014)

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

Volume 388, Issue 10061, Pages (December 2016)

Volume 372, Issue 9642, Pages (September 2008)

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study Dr Danielle V Clark, PhD, Hannah Kibuuka, MD, Monica.

Disease and stigma The Lancet Volume 354, (December 1999)

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled.

Volume 375, Issue 9732, Pages (June 2010)

Challenges to eliminate rabies virus infection in China by 2020

Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis Ulla Beijer, PhD, Achim Wolf, MSc, Dr.

Resuscitation at birth and cognition at 8 years of age: a cohort study

Volume 390, Issue 10094, Pages (August 2017)

Volume 379, Issue 9812, Pages (January 2012)

DEPARTMENT OF ERROR The Lancet Volume 362, Issue 9385, (August 2003)

Volume 12, Issue 6, Pages (June 2013)

Volume 385, Issue 9984, Pages (June 2015)

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie,

Volume 393, Issue 10171, Pages (February 2019)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 386, Issue 10011, Pages (December 2015)

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled,

Volume 6, Issue 4, Pages e230-e239 (April 2019)

Sven Pischke, Patrick Behrendt, Michael P Manns, Heiner Wedemeyer

Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Dr.

Volume 379, Issue 9822, Pages (March 2012)

Low-technology approaches

Volume 7, Issue 8, Pages (August 2008)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Effect of standard dose paracetamol versus placebo as antipyretic therapy on liver injury in adult dengue infection: a multicentre randomised controlled.

Volume 367, Issue 9518, Pages (April 2006)

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding,

Efficacy and safety of tribendimidine against Opisthorchis viverrini: two randomised, parallel-group, single-blind, dose-ranging, phase 2 trials Somphou.

Infections related to totally implantable venous-access ports

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled,

Volume 376, Issue 9737, Pages (July 2010)

Ebola control: rapid diagnostic testing

Volume 383, Issue 9930, Pages (May 2014)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 121, Issue 2, Pages (August 2001)

Presentation transcript:

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study Sumathi Sivapalasingam, MD, Mohamed Kamal, PhD, Rabih Slim, PhD, Romana Hosain, MD, Weiping Shao, PhD, Randall Stoltz, MD, Joseph Yen, PhD, Laura G Pologe, PhD, Yuan Cao, PhD, Michael Partridge, PhD, Giane Sumner, PhD, Leah Lipsich, PhD The Lancet Infectious Diseases Volume 18, Issue 8, Pages 884-893 (August 2018) DOI: 10.1016/S1473-3099(18)30397-9 Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile Cohort 1: REGN3470-3471-3479 3 mg/kg IV or placebo IV infused over 2 h. Cohort 2: REGN3470-3471-3479 15 mg/kg IV or placebo IV infused over 2 h. Cohort 3: REGN3470-3471-3479 60 mg/kg IV or placebo IV infused over 4 h. Cohort 4: REGN3470-3471-3479 150 mg/kg IV or placebo IV infused over 4 h. IV=intravenous. The Lancet Infectious Diseases 2018 18, 884-893DOI: (10.1016/S1473-3099(18)30397-9) Copyright © 2018 Elsevier Ltd Terms and Conditions

Figure 2 Mean log-scaled concentrations of total REGN3470, total REGN3471, and total REGN3479 in serum from healthy adults, by nominal time and treatment group Error bars show the SD of each mean. LLOQ=lower limit of quantification. The Lancet Infectious Diseases 2018 18, 884-893DOI: (10.1016/S1473-3099(18)30397-9) Copyright © 2018 Elsevier Ltd Terms and Conditions